Uncategorized
VIDEO: Ocular Therapeutix makes progress on drug candidates
BALTIMORE — Jonathan Talamo, MD, chief medical officer of Ocular Therapeutix, discusses the company’s pipeline development products, including its clinical development program for Dextenza (dexamethasone insert 0.4 mg), at the Association for Research in Vision and Ophthalmology meeting here.